Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. - Wikidata - awgldk - TriplyDB

Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.

Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q50996678

about

Efficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: A systematic review and meta-analysis Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA1C in Patients with Type 2 Diabetes After Taking an SGLT2 Inhibitor: A Retrospective, Longitudinal Study.Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment.Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus.SGLT2 inhibitors act from the extracellular surface of the cell membrane Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview.Functional expression of sodium-glucose transporters in cancer.A validated LC-MS/MS method for the determination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats.Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India.Canagliflozin-Induced Diabetic Ketoacidosis: Case Report and Review of the Literature Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates.Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.Characteristics and Impact Factors of Renal Threshold for Glucose Excretion in Patients with Type 2 Diabetes Mellitus.Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus.Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetes Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes.Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS).Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis.Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition.Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus.The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules.

P2860

Q26773558-7DC51E69-77B7-4D0E-A9FB-CCD96C376399 Q26777529-6885535E-EB7E-4474-B84B-FEFDDB5CD130 Q33732583-8E703850-65B3-4069-B001-F21BBC05E92D Q34105064-2FFE4A63-CBE2-4A8E-8396-F3D4C7796D62 Q34208581-F117BF50-176E-426C-AD54-424FBD58CD3A Q34397646-211E24A2-79BA-4FA0-A171-E87A21D8FD84 Q34400029-EC60C58D-3459-41B3-960E-F77433CE9042 Q34635575-52D0721C-880F-41F4-B793-4E2DF703C52D Q34699217-0DE6C31A-DF67-4EF8-854D-CFD9D7E60E32 Q34973750-6903A364-44B2-400A-8EA9-B5C569268275 Q35558413-DDEA6208-8ED3-4445-96EE-1589D9218F10 Q35831426-D5676EF5-AA8D-4200-87A6-EFE14F490DC9 Q35909986-0650827A-7096-40FA-9A40-6AA1359DCFB2 Q35962105-BD7E0364-E93F-41B7-A10A-7E3392377C7C Q35973288-4B68F954-1908-415E-9483-DDB9B2F304C0 Q36022710-56CC4C2D-2546-4000-9BCC-46FB368FA99D Q36059244-7AF1412D-B00F-49E2-B87A-6C343368E05D Q36762696-7435B2F8-8D66-4AB0-91F5-B23D59E68023 Q36867463-BF7C1ABE-F8C8-4BB8-BF18-B82CD7EC41A7 Q37231951-BA92AE9F-0DCC-4D4C-815B-007EFF203773 Q37456313-D052A1AD-5E9C-4E76-9965-A3CA5A2BDEA8 Q37524302-7F0E4BD1-D75E-437C-B7CA-7F19157E025B Q37588842-2CA9F1F5-8C94-4188-9869-E42A28317B76 Q37588847-211C013A-6107-4195-B4F8-A5C4B3AD3057 Q37677733-6CE5ACD1-9FC2-4043-A482-E07DF4961A09 Q37690751-2039A33A-5714-4C55-8F25-65C605509E22 Q37741752-7D57971F-B052-46B2-9167-EBA5F8C6453B Q38164682-32235EF6-26F6-430E-9ED8-17F5F0FD5091 Q38175467-310E48BE-F891-40AC-8B52-97DC52C4754C Q38212007-E7ED5FDD-9B6D-4BF4-91DD-060E40DF0E9F Q38254252-E3F8C4C6-3271-49E3-9F67-7B1BD5D5D3D3 Q38270203-000C7A94-C509-4A35-93DA-1E9765BED3A4 Q38371524-FFF61517-47A4-4DC1-9387-7C9B81EC1997 Q38383470-65144A19-1DB9-48B0-8181-60FDFBE225CA Q38515085-B1FA0B12-710C-479B-AB82-EC8A4D520314 Q38573559-1DB1813F-0470-46B1-9D71-B382585A3B3A Q38592327-4F8FA8BE-92BA-4E6C-B72B-5A30685E401C Q38796262-1A8DC808-B28F-4FB9-9961-9729B6F7FCA9 Q38798654-18C1D03A-BA5C-45AB-91DC-713E486E6959 Q38804903-B20C22C3-AE6C-4A54-AB80-866D431A899E

P2860

Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q50996678

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Pharmacokinetics and pharmacod ...... with type 2 diabetes mellitus.

@en

Pharmacokinetics and pharmacod ...... with type 2 diabetes mellitus.

@nl

type

label

Pharmacokinetics and pharmacod ...... with type 2 diabetes mellitus.

@en

Pharmacokinetics and pharmacod ...... with type 2 diabetes mellitus.

@nl

prefLabel

Pharmacokinetics and pharmacod ...... with type 2 diabetes mellitus.

@en

Pharmacokinetics and pharmacod ...... with type 2 diabetes mellitus.

@nl

P1433

Q50996678-28B05FA4-FC86-4897-9AC6-9E2F87F025A3

P1476

Q50996678-EBAC7628-440A-4F1D-97B0-1E196046E3C3

P2093

Q50996678-2A42A6A1-6C59-4A4C-BB88-467447177F40

Q50996678-2C2847D1-94E2-4245-A8EC-7AB129163C8E

Q50996678-376FA8B8-CE39-484F-92D7-460A436FEA10

Q50996678-6E27CE52-676E-4507-88D7-1DD07882E97C

Q50996678-9E93D801-7ADC-408D-A93E-00E9F73E2DAE

Q50996678-B01ABF1D-3912-4C5B-BB76-2DDA7E211355

Q50996678-FA6AB28E-1D36-4710-8900-4121C363B5A3

P304

Q50996678-2AB3FBE4-4F25-4D3F-AEDA-C6F0DE3CCEA7

P31

Q50996678-DA436B62-9CB5-427A-9827-32879B905494

P356

Q50996678-BF367788-8D6E-467B-81F7-70CFB04407B9

P433

Q50996678-D0A711AF-B2BC-42FE-81FE-57139A29FB28

P478

Q50996678-8821A265-E497-4087-BF81-7491E9C8CB55

P577

Q50996678-985E4E24-D226-453B-9603-CD9CA3C43E48

P5875

Q50996678-F4224EFE-39A9-407D-87AF-0263F333FE53

P698

Q50996678-5887FB92-885F-4AF6-AE27-27DAB4925C21

P921

Q50996678-A0490A40-6486-4E0A-B85A-9D742579FA7B

P356

P1433

The Journal of Clinical Pharmacology

P1476

Pharmacokinetics and pharmacod ...... with type 2 diabetes mellitus.

@en

P2093

Christopher R Curtin

http://www.w3.org/2001/XMLSchema#string

Damayanthi Devineni

http://www.w3.org/2001/XMLSchema#string

David Polidori

http://www.w3.org/2001/XMLSchema#string

Joseph Murphy

http://www.w3.org/2001/XMLSchema#string

Maria J Gutierrez

http://www.w3.org/2001/XMLSchema#string

Paul L Rothenberg

http://www.w3.org/2001/XMLSchema#string

Sarah Rusch

http://www.w3.org/2001/XMLSchema#string

P304

601-610

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.88

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236740562

http://www.w3.org/2001/XMLSchema#string

P698

23670707

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes